All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is pleased to present a visual abstract representing key data from the phase II HOVON146ALL trial (NCT03541083), evaluating blinatumomab added to prephase and consolidation therapy in newly diagnosed patients with ALL.
To download this visual abstract, click below.Download here
Combination therapy in patients with Philadelphia chromosome-negative B-ALL
Acute lymphoblastic leukemia (ALL) is a type of hematologic cancer of immature lymphocytes in the bone marrow, which most commonly affects children but also occurs in...
Does adding blinatumomab to frontline therapy improve survival outcomes for adults with B-ALL?
During the EHA 2022 Congress, the ALL Hub was pleased to speak to Anita Rijneveld, Erasmus MC, Rotterdam, NL. We asked, Does adding blinatumomab to...
Subscribe to get the best content related to ALL delivered to your inbox